who’s driving treatment? two co-occurring driver mutations in primary lung adenocarcinoma
Published 1 year ago • 158 plays • Length 14:06Download video MP4
Download video MP3
Similar videos
-
5:29
the role of driver mutations in nsclc treatment - 2022 program: lcvl
-
3:44
what is a driver mutation?
-
16:35
heterogeneity of nsclc and precipitating oncogenic driver mutations
-
8:03
driver mutations trump pd-l1 expression in lung adenocarcinoma
-
12:00
genomic characterization of brain metastases identifies drivers of metastatic lung adenocarcinoma
-
4:17
how does lung cancer affect the body?
-
4:01
how to spot red flag warning signs & symptoms of lung cancer... doctor o'donovan explains
-
4:27
lisa’s story: living with lung cancer
-
13:00
lung adenocarcinoma - mathew meyerson m.d, ph.d (part 1)
-
44:42
cancer genomics drives pediatric cancer precision medicine
-
6:04
the future of driver mutations in nsclc
-
1:06
dr. garon discusses driver mutations in sclc
-
0:58
ngs testing necessary for treatment of lung adenocarcinoma
-
18:41
extreme rare mutations in lung cancer (ros1, trk, her2): treatment opportunities
-
11:49
lung adenocarcinoma - mathew meyerson m.d, ph.d part 2
-
4:23
understanding mutations in lung cancer
-
59:37
icrn: introduction to cbioportal for cancer genomics
-
6:14
understanding biomarker testing in non-small cell lung cancer
-
23:04
tcga: comprehensive analysis of lung adenocarcinoma - matthew meyerson
-
3:30
understanding mutations and targeted therapy in lung cancer
-
26:13
therapeutic algorithm for nsclc adenocarcinoma
-
26:33
targeted therapy of lung cancer with or without driver mutations